# Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

> **NCT04221542** · PHASE1 · RECRUITING · sponsor: **Amgen** · enrollment: 479 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** AMG 509
- **DRUG:** Abiraterone
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT04221542
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-03-04
- **Primary completion:** 2030-03-22
- **Final completion:** 2032-03-21
- **Target enrollment:** 479 (ESTIMATED)
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04221542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04221542, "Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT04221542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*